Novavax (UK) Performance
| 0A3S Stock | 11.90 3.06 34.62% |
On a scale of 0 to 100, Novavax holds a performance score of 4. The company secures a Beta (Market Risk) of -1.57, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Novavax are expected to decrease by larger amounts. On the other hand, during market turmoil, Novavax is expected to outperform it. Please check Novavax's standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Novavax's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Novavax are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Novavax unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 0.05:1 | Last Split Date 2019-05-10 |
1 | Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research Development - StockTitan | 09/25/2024 |
2 | Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals - Yahoo Finance | 11/12/2024 |
3 | Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell - Yahoo Voices | 11/21/2024 |
| Total Cashflows From Investing Activities | -93 M |
Novavax |
Novavax Relative Risk vs. Return Landscape
If you would invest 1,190 in Novavax on September 2, 2024 and sell it today you would earn a total of 0.00 from holding Novavax or generate 0.0% return on investment over 90 days. Novavax is generating 0.7661% of daily returns and assumes 12.7747% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Novavax on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Novavax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novavax's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novavax, and traders can use it to determine the average amount a Novavax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.06
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 0A3S | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.77 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.77 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Novavax is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novavax by adding it to a well-diversified portfolio.
Novavax Fundamentals Growth
Novavax Stock prices reflect investors' perceptions of the future prospects and financial health of Novavax, and Novavax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novavax Stock performance.
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (1.54) % | ||||
| Current Valuation | 759.92 M | ||||
| Revenue | 885.19 M | ||||
| EBITDA | (243.25 M) | ||||
| Net Income | (657.94 M) | ||||
| Book Value Per Share | (3.29) X | ||||
| Cash Flow From Operations | (415.94 M) | ||||
| Earnings Per Share | (17.51) X | ||||
| Retained Earnings | (4.28 B) |
About Novavax Performance
Assessing Novavax's fundamental ratios provides investors with valuable insights into Novavax's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Novavax is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Novavax is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Novavax performance evaluation
Checking the ongoing alerts about Novavax for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novavax help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novavax is way too risky over 90 days horizon | |
| Novavax appears to be risky and price may revert if volatility continues | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 885.19 M. Net Loss for the year was (657.94 M) with loss before overhead, payroll, taxes, and interest of (156.04 M). | |
| Novavax generates negative cash flow from operations | |
| About 60.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell - Yahoo Voices |
- Analyzing Novavax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novavax's stock is overvalued or undervalued compared to its peers.
- Examining Novavax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novavax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novavax's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novavax's stock. These opinions can provide insight into Novavax's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.